Weekly ReportSep 7–13, 2026
Anesthesiology, week 37 edition
We read 198 papers and selected 3.
Summary
This week’s anesthesiology literature emphasized data-driven quality improvement, individualized anesthetic and respiratory management, and safer perioperative monitoring. The Swiss A-QUA registry demonstrated the value of nationwide anesthesia data infrastructure, while mechanistic work showed that isoflurane can substantially confound metabolic research. Randomized evidence also indicated that dexamethasone increases perioperative glycemic variability in older adults with diabetes, highlighting the need for targeted glucose surveillance. Across the week, emerging practice changes included weight-adjusted remimazolam dosing, phrenic-sparing regional anesthesia, objective sedation monitoring, and physiologically informed ventilation strategies.
Selected Articles
1. From data to quality: the story of A-QUA, Switzerland's Anaesthesia QUAlity initiative and database.
This retrospective analysis describes A-QUA, a nationwide Swiss anesthesia quality program. By the end of 2024, its case-based registry contained 2,045,026 cases from 54 centers, enabling standardized benchmarking, detection of recurrent data-quality problems, and analysis of regional and hospital variation in anesthesia practice and postoperative disposition.
Impact: The registry demonstrates how standardized, nationwide anesthesia data can support continuous quality improvement and perioperative research at a scale rarely available in anesthesiology. Its value lies in infrastructure, reproducibility, and the ability to identify actionable variation rather than in a single clinical association.
Clinical Implications: Anesthesia departments and health systems can use comparable routine data to identify preventable documentation or process errors, benchmark practice patterns, target quality-improvement interventions, and generate hypotheses for prospective safety research.
Key Findings
- The registry contained 2,045,026 anesthesia cases from 54 Swiss centers by the end of 2024.
- General anesthesia accounted for 74% of cases, regional anesthesia alone for 18%, and monitored anesthesia care for 8.5%.
- Plausibility checks identified recurrent preventable errors, while case studies demonstrated variation in anesthesia choice, timing, and postoperative destination across hospitals and regions.
2. A simple, anesthesia-free infusion technique for in vivo metabolic tracing.
This mechanistic study demonstrates that isoflurane anesthesia profoundly alters circulating and tissue metabolite profiles, including tissue-specific remodeling in the brain and pancreas. The authors developed a minimally invasive tail-vein catheterization method that permits multihour tracer infusion in awake, freely moving mice, reducing anesthesia-related metabolic confounding.
Impact: The paper challenges the assumption that anesthesia is metabolically neutral in preclinical research. Its awake-animal infusion method may improve reproducibility and validity across metabolic, pharmacologic, and disease-model studies.
Clinical Implications: The findings primarily affect basic and translational research rather than immediate clinical care. Investigators performing metabolic flux studies should consider anesthesia as a major experimental confounder and use awake infusion methods when scientifically and ethically appropriate.
Key Findings
- Isoflurane broadly decreased serum acylcarnitines and fatty acids while increasing selected amino acid metabolites and nucleotide species.
- Isoflurane induced coordinated but tissue-specific metabolic remodeling, including glycolytic changes in the brain and amino acid accumulation in the pancreas.
- A brief-anesthesia tail-vein catheterization technique enabled multihour tracer infusion in awake, freely moving mice.
3. Single-dose dexamethasone increases perioperative glycemic variability in older patients with diabetes undergoing lung surgery: a continuous glucose monitoring-based randomized controlled trial.
In this randomized controlled trial of 72 older adults with type 2 diabetes undergoing thoracoscopic lung resection, a single 8 mg dose of dexamethasone increased the maximum intraoperative glucose change and continuous glucose monitoring-derived glycemic variability. The findings identify transient glucose instability that may be underestimated by conventional intermittent glucose measurements.
Impact: Dexamethasone is widely used perioperatively, yet its dynamic glycemic effects in older patients with diabetes are incompletely characterized. The study provides clinically actionable cautionary evidence using continuous monitoring, while challenging reliance on intermittent glucose measurements alone.
Clinical Implications: In older patients with diabetes undergoing thoracic surgery, clinicians should balance the antiemetic and anti-inflammatory benefits of dexamethasone against increased glycemic variability. Continuous or more frequent glucose monitoring may be appropriate for high-risk patients, particularly when dexamethasone is administered.
Key Findings
- Intraoperative dexamethasone increased the maximum change in blood glucose compared with placebo.
- Continuous glucose monitoring showed greater perioperative glycemic variability after dexamethasone, including changes in standard deviation, coefficient of variation, and instability measures.
- Intermittent glucose testing may miss clinically relevant transient glycemic excursions in this vulnerable population.